World

The Future Of Possible

The mission of the Advanced Liver Diseases Study Group is to become the premier epidemiology, clinical, translational research, and treatment center for advanced liver diseases, cirrhosis, and portal hypertension in the world. Additionally, the mission is to mentor and educate clinician investigators in the field of hepatology.

Please Take Attention, This is just a Dummy Content, Not a real facts about Medicine.

The group is part of the Hepatic Vascular Cell Signaling Lab and Hepatocellular Carcinoma Lab programs as a major initiative involves collaboration with scientists to establish translational research.The activities of the Advanced Liver Diseases Study Group span from population-based research that utilizes the extensive resources of the Rochester Epidemiology Project to vascular endothelial pathophysiology. Additional research areas include the development of novel diagnostic tools, the conduct of therapeutic clinical trials, and health services research including economic analysis and health-related quality of life assessment.

Carcinoma Lab programs

  1. Understand the molecular and physiological mechanisms involved in cirrhosis and portal hypertension.
  2. Understand the mechanisms that underlie cirrhosis and portal hypertension by integrating basic science and clinical research programs.
  3. Develop and validate non-invasive diagnostic tools to evaluate and quantitate severity of liver fibrosis and portal hypertension.
  4. Develop and test new treatment options for patients with cirrhosis, esophageal varices, ascites, hepatic encephalopathy, hepatocellular carcinoma, hepatorenal syndrome, hepatopulmonary syndrome, portopulmonary hypertension, alcoholic hepatitis, acute liver failure, Budd-Chiari syndrome, hereditary hemorrhagic telangiectasia, and polycystic liver disease.
  5. Educate gastroenterology trainees, surgical trainees and postdoctoral fellows in the field of hepatology.
  6. Educate patients, practicing physicians, and investigators on advanced liver disease including cirrhosis and portal hypertension.

It is with truly mixed emotions that I announce the departure of Philip E. BournePhilip E. Bourne

It is with truly mixed emotions that I announce the departure of Philip E. Bourne, Ph.D., who will be leaving his post as NIH’s first Associate Director for Data Science to become the Stephenson Chair of Data Science, Director of the Data Science Institute, and Professor in the Department of Biomedical Engineering at the University of Virginia, Charlottesville.  I am happy for Phil to have this exceptional opportunity, and know that UVA will be well served by his depth of knowledge in data science.  At the same time, I am saddened that NIH will be losing his prowess and passion for tackling the opportunities and challenges of our increasingly data-driven biomedical research enterprise.

The group is part of the Hepatic Vascul

Phil will remain at NIH through April 30, 2017, and National Library of Medicine Director Patricia Flatley Brennan, R.N., Ph.D., will serve as Interim Associate Director for Data Science until a new appointment is made.

The group is part of the Hepatic Vascular Cell Signaling Lab and Hepatocellular Carcinoma Lab programs as a major initiative involves collaboration with scientists to establish translational research.The activities of the Advanced Liver Diseases Study Group span from population-based research that utilizes the extensive resources of the Rochester Epidemiology Project to vascular endothelial pathophysiology.

The mission of the Advanced Liver Diseases Study Group is to become the premier epidemiology, clinical, translational research, and treatment center for advanced liver diseases, cirrhosis, and portal hypertension in the world.

Related Articles

27 Comments

  1. Hiya, I am really glad I have found this info. Today bloggers publish only about gossips and internet and this is actually annoying. A good web site with interesting content, this is what I need. Thanks for keeping this web site, I’ll be visiting it. Do you do newsletters? Can not find it.

  2. obviously like your web-site however you have to check the spelling on several of your posts. Many of them are rife with spelling problems and I find it very bothersome to inform the reality nevertheless I will definitely come again again.

  3. obviously like your web-site but you need to check the spelling on quite a few of your posts. Several of them are rife with spelling issues and I find it very bothersome to tell the truth nevertheless I will definitely come back again.

  4. Thank you for sharing superb informations. Your site is very cool. I am impressed by the details that you have on this blog. It reveals how nicely you perceive this subject. Bookmarked this web page, will come back for extra articles. You, my pal, ROCK! I found just the info I already searched everywhere and simply couldn’t come across. What an ideal site.

  5. I would like to voice my gratitude for your kind-heartedness giving support to those individuals that really want assistance with this area. Your very own dedication to getting the message throughout came to be rather invaluable and has in most cases permitted people just like me to arrive at their dreams. Your new important instruction entails a lot to me and far more to my colleagues. Warm regards; from everyone of us.

  6. Good day! I could have sworn I’ve been to this site before but after browsing through some of the post I realized it’s new to me. Anyhow, I’m definitely glad I found it and I’ll be bookmarking and checking back often!

  7. Prodentim is the most recent dental health product. It helps to maintain healthy gums by using an ingredient that dentists at ProDentim UK developed.

  8. Wonderful beat ! I would like to apprentice while you amend your web site, how could i subscribe for a blog web site? The account helped me a acceptable deal. I had been tiny bit acquainted of this your broadcast offered bright clear idea

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Close